Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 9 Capecitabine 7 trastuzumab deruxtecan 6 Paclitaxel 6 Fulvestrant 6 pertuzumab 5 eribulin 5 Gemcitabine 4 Cyclophosphamide 4 sacituzumab govitecan 3 Vinorelbine 3 Doxorubicin 3 Docetaxel 3 Ado-Trastuzumab Emtansine 3 130-nm albumin-bound paclitaxel 3 selpercatinib 2 ribociclib 2 palbociclib 2 olaparib 2 larotrectinib 2 exemestane 2 abemaciclib 2 Fluorouracil 2 Epirubicin 2 Carboplatin 2 ulixertinib 1 tucatinib 1 trastuzumab biosimilar HLX02 1 trametinib 1 taxane 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Breast Neoplasms × RAD1901 × Clear all

NCT03778931 2025-09-15

EMERALD

Stemline Therapeutics, Inc.

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡